Neuro-critical care   

Considering the short half-life, at what point would it be deemed too late to administer any reversal agent, and to consider withholding it?

When would you consider using anticoagulation and for how long?

In FRAIL-AF, switching VKA therapy to a NOAC was associated with higher risk of bleeding in elderly, frail patients. 

In FRAIL-AF, participants were switched from VKA to dabigatran, rivaroxaban, apixaban, and edoxaban.